BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/26/2019 12:19:02 AM | Browse: 661 | Download: 718
 |
Received |
|
2019-03-23 06:36 |
|
Peer-Review Started |
|
2019-03-26 00:40 |
|
To Make the First Decision |
|
2019-09-11 00:10 |
|
Return for Revision |
|
2019-09-11 09:17 |
|
Revised |
|
2019-10-23 19:45 |
|
Second Decision |
|
2019-11-05 07:28 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-11-06 19:41 |
|
Articles in Press |
|
2019-11-06 19:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-12-18 02:53 |
|
Publish the Manuscript Online |
|
2019-12-26 00:19 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Rogelio González-González, Sandra López-Verdín, Jesús Lavalle-Carrasco, Nelly Molina-Frechero, Mario Isiordia-Espinoza, Ramón G Carreón-Burciaga and Ronell Bologna-Molina |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ronell Bologna-Molina, DDS, MSc, PhD, Postdoc, Professor, Research Scientist, Senior Scientist, Molecular Pathology, School of Dentistry, Universidad de la República de Uruguay (UDELAR), Las Heras 1925, Montevideo 11600, Montevideo, Uruguay. ronellbologna@odon.edu.uy |
| Key Words |
Ameloblastoma; B-raf proto-oncogene serine/threonine kinase; B-raf proto-oncogene serine/threonine kinase V600E; Additional mutations; Targeted therapies; |
| Core Tip |
Ameloblastoma is a common neoplasia that is developed from odontogenic epithelium. It is an aggressive and recurrent tumor that can present metastases or malignant transformation. This neoplasia is characterized by presenting different clinical and histological varieties as well as several mutations related to its behavior. Nowadays, there are several studies focused on targeted therapies against the mutations of this tumor, one of the most frequent ones being B-raf proto-oncogene serine/threonine kinase (BRAF) V600E, the treatment of which has been associated with good response. These targeted therapies are suitable for resistant tumors. This study focused on BRAF V600E mutations and its additional mutations and targeted therapies. |
| Publish Date |
2019-12-26 00:19 |
| Citation |
González-González R, López-Verdín S, Lavalle-Carrasco J, Molina-Frechero N, Isiordia-Espinoza M, Carreón-Burciaga RG, Bologna-Molina R. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review. World J Clin Oncol 2020; 11(1): 31-42 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i1/31.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i1.31 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
